By Suherman Candra Maholtra 
A comprehensive study involving more than 33,000 patients within the Veterans Affairs (VA) healthcare system has provided the most robust evidence to date regarding the efficacy of nicotinamide, a form of vitamin B3, in the prevention of nonmelanoma skin cancers. The research, led by investigators at Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System, suggests that early intervention with this widely available supplement could fundamentally alter the standard of care for patients at risk of developing basal cell carcinoma and cutaneous squamous cell carcinoma. By utilizing the extensive longitudinal records of the VA Corporate Data Warehouse, the research team was able to overcome long-standing data hurdles, revealing that while nicotinamide offers a modest 14% reduction in overall risk, its preventive power surges to 54% when administered immediately following a patient’s first skin cancer diagnosis.
The Evolution of Nicotinamide in Dermatological Practice
The journey of nicotinamide as a chemopreventive agent began in earnest nearly a decade ago. In 2015, the results of the Oral Nicotinamide to Reduce Actinic Cancer (ONTRAC) trial were published in the New England Journal of Medicine. That study, conducted in Australia, involved 386 participants and demonstrated that 500 milligrams of nicotinamide taken twice daily reduced the incidence of new nonmelanoma skin cancers by 23% over a 12-month period.
Following the 2015 trial, dermatologists worldwide began recommending the supplement to high-risk patients—specifically those who had already manifested multiple skin cancers. However, the ONTRAC study’s relatively small sample size and short duration left many questions unanswered. Clinical practitioners lacked large-scale, "real-world" data to confirm if these benefits translated to broader, more diverse populations over longer periods. Furthermore, because nicotinamide is an over-the-counter (OTC) supplement, tracking its usage through traditional medical records proved difficult, as patients often do not report supplement use, and physicians rarely code for it in standard billing systems.
Leveraging the VA Corporate Data Warehouse
To solve the problem of data scarcity, the research team turned to the Department of Veterans Affairs’ unique infrastructure. Unlike most private healthcare systems, the VA maintains a "formulary" that includes certain over-the-counter supplements. When a VA physician prescribes or recommends nicotinamide, it is often entered into the patient’s official electronic health record and fulfilled through the VA pharmacy system.
This allowed the researchers to identify a massive cohort of 33,833 veterans. The study focused on individuals who received a baseline treatment of 500 milligrams of nicotinamide twice daily for at least 30 days. This dosage mirrors the one used in the original 2015 clinical trial. The researchers then compared the health outcomes of 12,287 nicotinamide users against a control group of 21,479 veterans who did not take the supplement. By tracking the subsequent diagnoses of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC), the team was able to quantify the supplement’s impact with unprecedented statistical power.
Key Findings: The Power of Early Intervention
The study’s results, published in JAMA Dermatology, offer a nuanced view of how vitamin B3 interacts with skin cancer progression. The most striking discovery was the importance of timing. While the general risk reduction across the entire study population was a statistically significant 14%, the data revealed a dramatic spike in efficacy for a specific subgroup.
For patients who began taking nicotinamide after their very first skin cancer diagnosis, the risk of developing a subsequent skin cancer dropped by 54%. This suggests a "window of opportunity" where the supplement is most effective at stabilizing the skin’s cellular environment before cumulative damage leads to a cycle of recurring malignancies.
Interestingly, the study found that the protective benefits of nicotinamide appeared to diminish as the patient’s history of skin cancer grew more extensive. For those who had already developed numerous carcinomas before starting the supplement, the reduction in new cases was less pronounced. This finding challenges the current clinical trend of waiting until a patient is "heavily burdened" by skin cancer before suggesting nicotinamide.
Squamous Cell Carcinoma vs. Basal Cell Carcinoma
The research also highlighted a discrepancy in how nicotinamide affects different types of cancer. The protective effect was notably stronger for cutaneous squamous cell carcinoma (SCC) than for basal cell carcinoma (BCC).
SCC is the second most common form of skin cancer and is characterized by the abnormal, accelerated growth of squamous cells. While rarely fatal if caught early, SCC can be invasive and disfiguring. BCC, the most common form, grows more slowly and rarely spreads to other parts of the body but still requires surgical intervention. The finding that nicotinamide is particularly effective against SCC is significant, as SCC is often more aggressive and carries a higher risk of metastasis than BCC.
The Mechanism: How Vitamin B3 Protects the Skin
To understand why nicotinamide works, it is necessary to look at the impact of ultraviolet (UV) radiation on human cells. UV radiation from the sun causes DNA damage and depletes cellular energy in the form of adenosine triphosphate (ATP). When ATP levels drop, the skin’s natural DNA repair mechanisms are compromised, and the local immune response is suppressed, creating an environment ripe for the development of cancerous mutations.
Nicotinamide is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for ATP production. By replenishing NAD+ levels, nicotinamide helps the skin maintain the energy levels required for DNA repair and prevents the immune suppression typically caused by UV exposure. Essentially, the supplement acts as a fuel source for the skin’s own defense systems.
Challenges for Immunocompromised Populations
The study also delved into a high-risk sub-population: organ transplant recipients. These patients must take lifelong immunosuppressant medications to prevent organ rejection, which unfortunately leaves them at a significantly higher risk for skin cancer—sometimes up to 100 times higher than the general population.
The research team evaluated 1,334 immunocompromised patients within the VA system. While the data showed that early use of nicotinamide was linked to fewer cases of SCC in this group, the overall reduction in risk did not reach the threshold of statistical significance. This suggests that while nicotinamide may provide some benefit, the profound immune suppression in transplant patients may override the supplement’s protective mechanisms, requiring more aggressive or different preventive strategies for this group.
Shifting the Clinical Paradigm
The implications of this study are poised to change how dermatologists approach preventive care. Dr. Lee Wheless, the study’s corresponding author and assistant professor at Vanderbilt University Medical Center, noted that the current lack of universal guidelines has led to inconsistent application of nicotinamide therapy.
"These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier," Dr. Wheless stated. He emphasized that while the findings are encouraging, the medical community still needs to refine its ability to identify which patients are most likely to benefit. Statistics show that roughly half of patients who develop one skin cancer will go on to develop multiple others. Identifying this 50% early and starting them on nicotinamide could drastically reduce the total burden of disease.
Public Health and Economic Implications
Beyond the clinical benefits for individual patients, the widespread adoption of nicotinamide could have substantial public health and economic impacts. Nonmelanoma skin cancer is the most common malignancy in the United States, with more than 5 million cases diagnosed annually. The cost of treating these cancers—primarily through surgical procedures like Mohs surgery—runs into the billions of dollars each year.
Nicotinamide is an inexpensive, over-the-counter supplement with a high safety profile. Unlike niacin (another form of vitamin B3), nicotinamide does not cause "flushing" or low blood pressure, making it well-tolerated by most patients. If early intervention can reduce the incidence of secondary skin cancers by half, the potential savings for healthcare systems like the VA and Medicare are immense.
Chronology of Evidence and Future Research
The timeline of nicotinamide research shows a clear trajectory toward validation:
- 2012-2014: Phase II trials suggest nicotinamide reduces actinic keratoses (precancerous lesions).
- 2015: The ONTRAC trial provides the first high-level evidence of a 23% reduction in NMSC.
- 2016-2022: Small-scale observational studies and meta-analyses show mixed results, leading to calls for larger population studies.
- 2024: The VA study of 33,833 veterans provides "real-world" confirmation and identifies the critical importance of early intervention.
Moving forward, researchers aim to conduct prospective trials that specifically target patients after their first diagnosis to confirm the 54% risk reduction observed in the VA data. Additionally, further study is needed to determine the optimal duration of treatment and whether the benefits persist if a patient stops taking the supplement.
Conclusion
The Vanderbilt and VA study represents a significant milestone in dermatological oncology. By providing evidence that nicotinamide’s efficacy is highest when used as a primary preventive measure following an initial diagnosis, the research offers a clear path toward reducing the global burden of skin cancer. As clinical guidelines evolve to reflect these findings, nicotinamide may soon become a cornerstone of early-stage skin cancer management, offering a simple, cost-effective, and powerful tool in the fight against the world’s most common cancer.